CG0070 Plus Pembrolizumab Produces Durable Responses in BCG-Unresponsive NMIBC
Roger Li, MD, discusses how the synergistic mechanism of pembrolizumab plus CG0070 could address unmet needs in BCG-unresponsive NMIBC, safety and efficacy data for the combination from the CORE-001 trial, and how those data support planned research efforts for CG0070 in this space.
Source: onclive.com